US 12,233,085 B2
Application of hyaluronic acid in preparing medicines for preventing or treating ferroptosis-related diseases
Zhiqiang Liu, Beijing (CN); Zengqiang Yuan, Beijing (CN); Xiaowen Xing, Beijing (CN); Bingshui Xiu, Beijing (CN); and Shihong Liu, Beijing (CN)
Assigned to ACADEMY OF MILITARY MEDICAL SCIENCES, ACADEMY OF MILITARY SCIENCES OF CHINESE PLA, Beijing (CN); and BEIJING JIUYU ONCOLGY CO LTD, Beijing (CN)
Filed by ACADEMY OF MILITARY MEDICAL SCIENCES, ACADEMY OF MILITARY SCIENCES OF CHINESE PLA, Beijing (CN); and BEIJING JIUYU ONCOLGY CO LTD, Beijing (CN)
Filed on Sep. 4, 2023, as Appl. No. 18/460,637.
Application 18/460,637 is a continuation of application No. PCT/CN2022/078780, filed on Mar. 2, 2022.
Claims priority of application No. 202110241981.9 (CN), filed on Mar. 4, 2021.
Prior Publication US 2023/0405041 A1, Dec. 21, 2023
Int. Cl. A61K 31/728 (2006.01); A61P 25/00 (2006.01); A61P 25/28 (2006.01); A61P 31/12 (2006.01)
CPC A61K 31/728 (2013.01) [A61P 25/00 (2018.01); A61P 25/28 (2018.01); A61P 31/12 (2018.01)] 5 Claims
OG exemplary drawing
 
1. A method for inhibiting ferroptosis, including administering an effective amount of an anti-ferroptosis medicine comprising hyaluronic acid or hyaluronates to an object in need of treatment, wherein a number-average molecular weight of the hyaluronic acid or the hyaluronates ranges from 730 kD-1500 kD and concentration of hyaluronic acid or its salts ranges from 0.1% to 0.5% weight/volume, wherein the medicines are used for treating cerebral hemorrhage or treating renal failure or treating a neurodegenerative disease; wherein the medicine further comprises ferroptosis inhibitors selected from the group consisting of deferoxamine or Ferrostatin-1 and pharmaceutically acceptable excipients.